Is Moleculin Biotech Inc (MBRX) overvalued? · $8.2M cap
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
This page asks whether Moleculin Biotech Inc (MBRX) looks expensive on cached numbers — not a short thesis.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
MBRX currently screens at market cap $8.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MBRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MBRX stock page for the full model, not this heading.
Not investment advice.